NADPH oxidase 2 mediates cardiac sympathetic denervation and myocyte autophagy, resulting in cardiac atrophy and dysfunction in doxorubicin-induced cardiomyopathy - Ma, Yuan; Zhao, Hui-Ping; Yang, Li-Guo; Li, Lu; Wang, Ai-Lin; Zhang, Xiao-Juan; Wang, Ke; Yang, Bin; Zhu, Zong-Feng; Zhang, Pei-Jun; Wang, Jia-Pu; Chi, Rui-Fang; et al. (Scientific reports, 2024)
Keywords: 631/443/592/75/230; 631/443/592/75/74; Animals; Antineoplastic drugs; Atrophy; Autophagy; Cardiomyopathies - chemically induced; Cardiomyopathies - metabolism; Cardiomyopathy; Cardiotoxicity; Congestive heart failure; CYBB protein; Denervation; Doxorubicin; Doxorubicin - pharmacology; Heart diseases; Humanities and Social Sciences; Mice; Mice, Inbred C57BL; Mice, Knockout; multidisciplinary; Myocytes; Myocytes, Cardiac - metabolism; NAD(P)H oxidase; NADPH Oxidase 2 - genetics; NADPH Oxidase 2 - metabolism; NADPH Oxidase 4 - metabolism; Norepinephrine; Norepinephrine transporter; Oxidative Stress; Science; Science (multidisciplinary); Survival; Sympathectomy; Sympathetic nerves; Tyrosine 3-monooxygenase